{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:50:35Z","timestamp":1792050635478,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ucl.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:05:02Z","timestamp":1716005102000},"page":"367-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["New Therapeutic Horizons for Advanced or Metastatic Penile Cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Nicholas","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Atiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clinicians"},{"issue":"7","key":"10.1016\/j.ucl.2024.03.005_bib2","doi-asserted-by":"crossref","DOI":"10.2196\/34874","article-title":"Global pattern and trends in penile cancer incidence: population-based study","volume":"8","author":"Fu","year":"2022","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","article-title":"Penile cancer","volume":"7","author":"Thomas","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.005_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European association of urology-american society of clinical oncology collaborative guideline on penile cancer: 2023 update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.ucl.2024.03.005_bib5","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.005_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2007.02.006","article-title":"Neoadjuvant chemotherapy in advanced penile carcinoma","volume":"52","author":"Leijte","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.005_bib7","first-page":"1335","article-title":"Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma","volume":"177","author":"Bermejo","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2024.03.005_bib8","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdn149","article-title":"A\u00a0phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)","volume":"19","author":"Theodore","year":"2008","journal-title":"Ann Oncol"},{"issue":"11 Pt B","key":"10.1016\/j.ucl.2024.03.005_bib9","first-page":"E661","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.005_bib10","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1756287212441235","article-title":"Chemotherapy in penile cancer","volume":"4","author":"Hakenberg","year":"2012","journal-title":"Ther Adv Urol"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.005_bib12","first-page":"1347","article-title":"Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma","volume":"184","author":"Graafland","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.005_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jso.20414","article-title":"Prognostic factors in node-positive carcinoma of the penis","volume":"93","author":"Pandey","year":"2006","journal-title":"J\u00a0Surg Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2024.03.005_bib14","doi-asserted-by":"crossref","first-page":"TPS7","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS7","article-title":"The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases","volume":"40","author":"Pettaway","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","article-title":"The international penile advanced cancer trial (Inpact): rationale and current status","volume":"5","author":"Canter","year":"2019","journal-title":"European Urology Focus"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","article-title":"Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes","volume":"85","author":"Wang","year":"2015","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.ucl.2024.03.005_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2024.03.005_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum Pathol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2024.03.005_bib19","first-page":"4","article-title":"Penile squamous cell carcinoma (Pscc) with elevated tumor mutational burden (Tmb): A genomic landscape study","volume":"41","author":"Spiess","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"24","key":"10.1016\/j.ucl.2024.03.005_bib20","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.34982","article-title":"Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers","volume":"129","author":"Nazha","year":"2023","journal-title":"Cancer"},{"issue":"31","key":"10.1016\/j.ucl.2024.03.005_bib21","first-page":"4872","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (The pericles study): a phase ii trial","volume":"41","author":"de Vries","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"key":"10.1016\/j.ucl.2024.03.005_bib22","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1016\/j.annonc.2021.08.111","article-title":"715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcS\u00e9 prospective program","volume":"32","author":"Pouessel","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.005_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.005_bib24","first-page":"790","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase iii keynote-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2024.03.005_bib25","first-page":"TPS14","article-title":"A\u00a0phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial","volume":"41","author":"Maluf","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.005_bib26","first-page":"TPS5094","article-title":"A\u00a0phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (Epic trial)","volume":"40","author":"Renninson","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"31","key":"10.1016\/j.ucl.2024.03.005_bib27","first-page":"3672","article-title":"Phase i study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3747\/co.v17i1.471","article-title":"Egfr overexpression in squamous cell carcinoma of the penis","volume":"17","author":"Lavens","year":"2010","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/14728222.2013.783571","article-title":"egfr mutational status in penile cancer","volume":"17","author":"Di Lorenzo","year":"2013","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.21037\/tau.2017.03.92","article-title":"Beyond chemotherapy for advanced disease\u2014the role of EGFR and PD-1 inhibitors","volume":"6","author":"Gu","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","article-title":"Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib33","first-page":"541","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2024.03.005_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","article-title":"Second line salvage systemic therapy for advanced penile cancer","volume":"40","author":"Chahoud","year":"2022","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2024.03.005_bib35","first-page":"TPS4607","article-title":"A\u00a0phase II study of olaparib (Azd2281) in patients (Pts) with metastatic\/advanced urothelial carcinoma and other genitourinary (Gu) tumors with DNA-repair defects","volume":"41","author":"Chandran","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"9","key":"10.1016\/j.ucl.2024.03.005_bib36","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-20-4004","article-title":"Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma","volume":"27","author":"Chahoud","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","article-title":"Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations","volume":"21","author":"Ali","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.ucl.2024.03.005_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221127254","article-title":"An update on treatment of penile cancer","volume":"14","author":"Chadha","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2024.03.005_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ajur.2022.03.006","article-title":"Penile cancer: Updates in systemic therapy","volume":"9","author":"Joshi","year":"2022","journal-title":"Asian J Urol"},{"issue":"14","key":"10.1016\/j.ucl.2024.03.005_bib40","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.3390\/cancers15143713","article-title":"The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma\u2014A Systematic Review","volume":"15","author":"Parza","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ucl.2024.03.005_bib41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(09)70227-X","article-title":"Development of therapeutic HPV vaccines","volume":"10","author":"Trimble","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib43","first-page":"608","article-title":"Combination Therapies for HPV-Associated Malignancies","volume":"12","author":"Smalley Rumfield","year":"2021","journal-title":"J\u00a0Clin Cell Immunol"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.005_bib44","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ucl.2024.03.005_bib45","doi-asserted-by":"crossref","unstructured":"Strauss J, Floudas C, Sater H, et al. Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies, J Clin Oncol, 40 (suppl 16), 2022, abstr 2518.","DOI":"10.1200\/JCO.2022.40.16_suppl.2518"},{"key":"10.1016\/j.ucl.2024.03.005_bib46","article-title":"766 Phase I\/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies","volume":"10","author":"Strauss","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.ucl.2024.03.005_bib47","doi-asserted-by":"crossref","unstructured":"Floudas C., Strauss J., Allen C., et al., \"First-in-human phase I\/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent\/metastatic (R\/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant\/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).\" J Clin Oncol 39(15_suppl): TPS6092.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS6092"},{"issue":"7","key":"10.1016\/j.ucl.2024.03.005_bib48","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ucl.2024.03.005_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/EDBK_321115","article-title":"Adoptive cellular therapy for solid tumors","volume":"41","author":"Bear","year":"2021","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"8","key":"10.1016\/j.ucl.2024.03.005_bib50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41585-022-00617-x","article-title":"Immune-based therapies in penile cancer","volume":"19","author":"Joshi","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"30","key":"10.1016\/j.ucl.2024.03.005_bib51","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.ucl.2024.03.005_bib53","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib54","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A\u00a0phase ii study of tumor-infiltrating lymphocyte therapy for human papillomavirus\u2013associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2024.03.005_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107481","article-title":"Expansion of tumor-infiltrating lymphocytes (Til) from penile cancer patients","volume":"94","author":"Aydin","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"43","key":"10.1016\/j.ucl.2024.03.005_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390094","article-title":"Rise of antibody-drug conjugates: the present and future","author":"Shastry","year":"2023","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"1","key":"10.1016\/j.ucl.2024.03.005_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"8","key":"10.1016\/j.ucl.2024.03.005_bib59","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"17_suppl","key":"10.1016\/j.ucl.2024.03.005_bib60","first-page":"LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-dxd) in patients (Pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017517","article-title":"Alternative her\/pten\/akt pathway activation in hpv positive and negative penile carcinomas","volume":"6","author":"Stankiewicz","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2024.03.005_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113360","article-title":"The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy","volume":"194","author":"Tan","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2024.03.005_bib63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ucl.2024.03.005_bib64","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"Trophy-u-01: a phase ii open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2024.03.005_bib65","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ucl.2024.03.005_bib66","article-title":"Metastatic penile squamous cell carcinoma responsive to enfortumab vedotin","volume":"24","author":"Fahey","year":"2023","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.ucl.2024.03.005_bib67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0825859720946887","article-title":"A\u00a0lack of palliative therapy use in patients with advanced penile cancer","volume":"36","author":"Davaro","year":"2021","journal-title":"J\u00a0Palliat Care"},{"key":"10.1016\/j.ucl.2024.03.005_bib68","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.urology.2023.07.006","article-title":"Predicting limited survival following inguinal lymph node dissection in penile cancer: should we revisit the goals of care?","volume":"180","author":"Hugar","year":"2023","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2024.03.005_bib69","first-page":"824","article-title":"Enlisting urologists to improve palliative care services integration in the care of advanced penile cancer","volume":"209","author":"Davaro","year":"2023","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2024.03.005_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2022.151288","article-title":"Is there a role for palliative services and supportive care in managing advanced penile cancer?","volume":"38","author":"Hugar","year":"2022","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ucl.2024.03.005_bib71","unstructured":"The Institute for Cancer Research, UK. The International Penile Advanced Cancer Trial (InPACT\/ECOG-ACRIN Cancer Research Group trial EA8134 v. 02\/16\/23; NCT02305654). https:\/\/ecog-acrin.org\/wp-content\/uploads\/2021\/01\/EA8134-Physician-Fact-Sheet.pdf."}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014324000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:52:20Z","timestamp":1719283940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014324000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0094014324000302"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Therapeutic Horizons for Advanced or Metastatic Penile Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}